An updated version of the SimpleScreen CRC blood test is showing improved ability to spot trouble before it turns into cancer. Presented at the ACG 2026 Annual Scientific Meeting, the upgraded test showed better sensitivity for advanced precancerous lesions — a meaningful step toward making blood-based screening a more effective tool. It's still not as accurate as colonoscopy or stool-based tests, but offers a solid option for patients who won't do either.
The SimpleScreen CRC blood test just got a meaningful upgrade. Researchers presented updated performance data at the ACG 2026 Annual Scientific Meeting, showing that assay and algorithm enhancements to the FDA-approved test improved its ability to detect advanced precancerous lesions (APLs) — the kind of early findings that, if caught, can actually prevent colorectal cancer from developing in the first place.
The updated test still isn't a replacement for colonoscopy or fecal immunochemical testing (FIT), which remain the gold standard for CRC screening. But for patients who refuse or can't access those options, the improved SimpleScreen offers a meaningful alternative — and experts say it may be nudging blood-based testing closer to "cancer prevention" territory for the first time.
By the Numbers:
Why it matters: Blood-based CRC screening tests have long been criticized for missing precancerous lesions, since polyps don't shed markers into the bloodstream the way invasive cancers do. The fact that this updated test is detecting APLs at a meaningfully higher rate suggests the technology is genuinely improving — and could eventually help bring more patients into the screening fold, even if they're not ready for a colonoscopy.
